Stockscreener 앱 받기
61.73
1.01%
0.62
시간 외 거래:
59.31
-2.42
-3.92%
전일 마감가:
$61.11
열려 있는:
$60.89
하루 거래량:
2.17M
Relative Volume:
0.81
시가총액:
$11.86B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
22.95
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
-3.67%
1개월 성능:
+8.58%
6개월 성능:
+5.23%
1년 성능:
-10.69%
1일 변동 폭
$60.59
$63.21
1주일 범위
$59.56
$66.28
52주 변동 폭
$50.76
$73.51
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
61.73 | 11.74B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-20 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-09-08 | 개시 | H.C. Wainwright | Neutral |
| 2025-09-03 | 개시 | Raymond James | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin Pharmaceutical EVP Trades $381K In Company Stock - Benzinga
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About BioMarin Pharm - GuruFocus
Friberg, Biomarin Pharmaceutical EVP, sells $381k in stock By Investing.com - Investing.com Australia
Insider Selling: BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Sells 6,326 Shares of Stock - MarketBeat
Davis, Biomarin Pharmaceutical EVP sells $1.6m in shares - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo - Yahoo Finance
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Primecap Management Co. CA - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2025 Earnings Call Transcript - Insider Monkey
BioMarin Reports Mixed Q4 Results with Earnings Miss - Intellectia AI
Sanford C. Bernstein Increases BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $94.00 - MarketBeat
Guggenheim Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price - MarketBeat
Bernstein raises BioMarin stock price target on valuation outlook - Investing.com India
Bernstein raises BioMarin stock price target on valuation outlook By Investing.com - Investing.com South Africa
Is BioMarin Pharmaceutical (BMRN) Pricing Match Recent Share Rebound And DCF Upside Potential - Yahoo Finance
HC Wainwright Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $55.00 - MarketBeat
H.C. Wainwright cuts BioMarin stock price target on competition - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $95.00 at Oppenheimer - Defense World
BioMarin shuts down one-and-done hemophilia gene therapy after failing to sell itSan Francisco Business Times - The Business Journals
BioMarin Leans Into BD As Voxzogo Competition Intensifies - Citeline News & Insights
BioMarin Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder - Fierce Pharma
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - TradingView
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Bitget
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $95.00 Price Target at Oppenheimer - MarketBeat
BioMarin to Participate in Four Upcoming Investor Conferences in March - PR Newswire
BioMarin Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Stifel raises BioMarin stock price target to $68 on Fold deal value - Investing.com India
Earnings call transcript: BioMarin misses Q4 2025 EPS forecast, stock dips - Investing.com Nigeria
Earnings call transcript: BioMarin misses Q4 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
BioMarin Pharmaceutical Q4 Earnings Call Highlights - Yahoo Finance
BioMarin: Q4 Earnings Snapshot - kare11.com
BMRN: 2025 revenue grew 13% with strong profitability; 2026 set for further growth and pipeline advances - TradingView
BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates - Finviz
BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Earnings Results, Misses Estimates By $1.04 EPS - MarketBeat
BioMarin Pharmaceutical Posts Q4 Loss - Nasdaq
BioMarin posts mixed Q4 results, shares edge lower By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Q4 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Issued - marketscreener.com
BioMarin posts mixed Q4 results, shares edge lower - Investing.com
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: A 38.69% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
BioMarin earnings loom with estimates falling on Voxzogo worries By Investing.com - Investing.com South Africa
BioMarin earnings loom with estimates falling on Voxzogo worries - Investing.com India
(BMRN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Skandinaviska Enskilda Banken AB publ Has $2.34 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Vanguard Group Inc. - MarketBeat
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오마린 주식 (BMRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Davis George Eric | EVP, Chief Legal Officer |
Feb 26 '26 |
Sale |
61.36 |
26,061 |
1,599,103 |
72,453 |
1.18%
0.45%
자본화:
|
볼륨(24시간):